The clinical implications of the Prostate Cancer Prevention Trial (PCPT) [11]

BJU International

Volumn 93, Issue 7, 2004, Pages 1120-1121

  Pitts Jr , W R ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FINASTERIDE; PLACEBO; ENZYME INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER GRADING; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CLINICAL EXAMINATION; CLINICAL TRIAL; DIAGNOSTIC APPROACH ROUTE; DRUG EFFECT; DRUG EFFICACY; ECHOGRAPHY; HUMAN; LETTER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY; RECTUM BIOPSY; RISK ASSESSMENT; SCORING SYSTEM; MALE; NOTE; PROSTATE TUMOR;

CLINICAL TRIALS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 2542560453     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.4834k.x     Document Type: Letter

References (15)

1. Marberger M, Adolfson J, Borkowski A et al. The clinical implications of the Prostate Cancer Prevention Trial (PCPT). BJU Int 2003; 92: 667-71
2. Silver RI, Wiley EL, Dans DL et al. Expression and regulation of steroid 5 alpha reductase 2 in prostate disease. J Urol 1994; 152: 438
3. Luo J, Dunn TA, Walsh PC et al. Decreased gene expression of steroid 5 alpha reductase 2 in human prostate cancer: Implications for finasteride therapy of prostate cancer. The Prostate 2003; 57: 134-9
4. Thompson IM, Goodman PJ, Tangen CM et al. The influence of finasteride on the development of prostate cancer. NEJM 2003; 349: 213-32
5. Ross RK, Bernstein L, Lobo RA et al. 5 alpha reductase activity and risk of prostate cancer among Japanese and U.S. white and black males. Lancet 1992; 339: 887
6. Harris R, Lohr K. Screening for prostatic cancer. An update of the evidence for the U.S. preventive service task force. Ann Int Med 2002; 137: 917-28
7. Pitts WR Jr. Letter Re: Outcome research after radical retropubic prostatectomy for prostate cancer. J Nat Cancer Inst 1998; 90: 1107
8. Pitts WR Jr. Letter Re. Editorial: Prostate Puzzle. J Urol 1998; 160: 1441
9. Han M, Partin AW, Chan DY, Walsh PC. Evaluation of decreasing incidence of positive surgical margins in a large (9035) retropubic prostatectomy series. J Urol 2004; 171: 23-6
10. Garnick NB, Fair WR. Prostate cancer emerging concepts. Part I. Ann Int Med 1996; 125: 118-25
11. Holmberg L, Bill-Axelson A, Helgisen F et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. NEJM 2002; 347: 781-9
12. Pitts WR Jr. Letter Re: Chemoprevention of urological cancer. J Urol 2000; 163: 1260-1
13. Pitts WR Jr. Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective. BJU Int 2001; 88: 985-6
14. Walsh PC. Comments on PLESS - Proscar Longterm Safety and Efficacy Study. J Urol 1999; 161: 350
15. Pitts WR Jr. Letter Re: Back to the future - the role of complementary medicine in urology. J Urol 2000; 164: 461